E10030 sham injection: Clinical Trials

1 trial of E10030 sham injection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Terminated 1

Follow E10030 sham injection: new trials by email Literature Review of E10030 sham injection trials Research Report on E10030 sham injection

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
E10030, bevacizumab or aflibercept, E10030 sham injection - Age-Related Macular Degeneration
Phase 3TerminatedOphthotech Corporation6452014-05-012024-10-31

Conditions studied

Choroidal Neovascularization (1)  ·  Macular Degeneration (1)

Sponsors

Ophthotech Corporation (1)

Countries

Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Brazil (1)  ·  Canada (1)  ·  Colombia (1)  ·  Croatia (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)

Results publications

PMID 30957581